MIMI I-NAN HU to Mutation
This is a "connection" page, showing publications MIMI I-NAN HU has written about Mutation.
Connection Strength
0.152
-
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 08; 9(8):491-501.
Score: 0.049
-
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 07; 8(7):836-849.
Score: 0.039
-
Updates in the management of medullary thyroid cancer. Clin Adv Hematol Oncol. 2011 May; 9(5):391-4.
Score: 0.024
-
Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am. 2008 Jun; 37(2):481-96, x-xi.
Score: 0.020
-
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
Score: 0.010
-
All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. Fam Cancer. 2017 04; 16(2):283-289.
Score: 0.009